Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer (PALAVY)

NCT04841148 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.

NCT NCT04841148
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04841148 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer (PALAVY)
Lead sponsor
Abramson Cancer Center at Penn Medicine
Phase
Phase 2
Overall status
Recruiting
Start date
June 1, 2021
Completion date
May 31, 2028
Enrollment
96 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer